Navigation Links
AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Date:11/13/2008

---------

Net loss per share from

continuing operations

Basic and diluted (0.26) (0.15) (0.85) (0.34)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Net loss per share

Basic and diluted (0.26) (0.16) (0.85) (0.35)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Weighted average number

of shares

Basic and diluted 53,187,470 53,184,803 53,187,470 53,181,248

-------------------------------------------------------------------------

-------------------------------------------------------------------------

* Stock-based

compensation costs

included in:

Research and

development 50 64 166 180

Selling, general

and administra-

tive 52 447 78 1,312

-------------------------------------------------------------------------

102 511 244 1,492

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Consolidated Statement of Comprehensive Income

Three months ended Nine months ended

Sept. 30, Sept. 30,

(Unaudited) 2008 2007 2008 2007

-------------------------------------------------------------------------

-------------------------------------------------------------------------

$ $
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
2. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
4. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
5. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
6. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
8. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
9. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
10. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
11. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014 Applied Silicone Corporation, ... for the medical device and critical healthcare market, ... the implantable medical device market. The Dual ... delivering a silicone gel with improved fracture resistance, ... technology consists of two crosslinked networks working in ...
(Date:9/15/2014)... 15 septembre 2014 La deuxième édition ... (semaine internationale sur la sensibilisation au plasma) ... conjointe de la Plasma Protein Therapeutics Association ... , l,IPAW vise à : , ... la collecte du plasma-aphérèse , Reconnaître la ...
(Date:9/15/2014)... -- The second annual International Plasma Awareness Week (IPAW) ... of the Plasma Protein Therapeutics Association (PPTA) ... to: , Raise global awareness about source ... donors in saving and improving lives , Increase ... Member companies are planning a variety ...
(Date:9/14/2014)... UMBC’s Biotechnology Graduate Programs’ ... 21, 2014, from 12:00 to 1:00 p.m. EDT. The ... curriculum and practice-oriented instruction, designed for working professionals. Participants ... advance their career in the biotechnology industry. , If ... , About UMBC’s Biotechnology Graduate Programs, UMBC offers a ...
Breaking Biology Technology:Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 3International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2
... (Nasdaq: ONXX ) today announced that it ... on Thursday, June 26, at,10:45 a.m. Eastern Time. ... presentation on our website at:, http://www.onyx-pharm.com/wt/page/event_calendar ... on 15 minutes early in order to,register and ...
... in London on Friday, June 20, 2008, NEW ... of the,leading plaintiffs, litigation law firms in America, filed ... a New York City Fire,Department Emergency Medical Technician whose ... EMT Ernest Armstead, was one,of the many brave responders ...
... Calif., June 19 The,Fifth Annual Healthcare Unbound ... Innovation (TCBI), will feature the coming together of,consumer ... help manage,diseases. The Conference will take place at ... will include a diverse representation of the many,business ...
Cached Biology Technology:Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca 2Fifth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Disease Management & Wellness Promotion 2Fifth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Disease Management & Wellness Promotion 3
(Date:9/15/2014)... the subsequent rapid decrease in the water level of ... square kilometres of new, fertile land in eastern Finland. ... researchers has studied the role that the decrease in ... and humans. After dramatic shifts in the waterways, human ... rise to a new, innovative culture. This stemmed from ...
(Date:9/15/2014)... weighing as much as 170 tons, the blue whale is ... heaviest living thing ever seen on Earth. So there,s no ... fish larvae, which measure millimeters in length and tip the ... Not so fast, says L. Mahadevan, the Lola England de ... and of Physics. , Using simple hydrodynamics, a team ...
(Date:9/15/2014)... cardiovascular disease (CVD) claims 17 million lives each year, ... 9.4 million. 1 New research presented by international ... Montpellier, France on September 15, 2014, suggests that milk ... , At the Milk and Dairy Products in ... risk for hypertension and CVD was examined by Dr. ...
Breaking Biology News(10 mins):The creation of the Vuoksi River preceded a significant cultural shift 2The science behind swimming 2The science behind swimming 3Dairy consumption linked to lower blood pressure and cardiovascular disease risk 2
... research into cheetah cub survival has refuted the theory that ... cannot coexist in conservation areas. The study, published in the ... Kgalagadi Transfrontier Park were seven times more likely to survive ... found to be the cubs, main predatory threat. Previously, ...
... MA -- Researchers at MIT and Brigham and Women,s ... of intestinal stem cells, then stimulate them to develop ... intestinal cells. Using these cells, scientists could develop and ... colitis. The small intestine, like most other body ...
... approach to mapping how proteins interact with each other, ... aid in the design of new drugs for diseases ... artificial amino acids, the Salk scientists determine the detailed ... the molecule that turns it on. The switch--corticotrophin releasing ...
Cached Biology News:Researchers unlock a new means of growing intestinal stem cells 2Researchers unlock a new means of growing intestinal stem cells 3Salk scientists crack riddle of important drug target 2Salk scientists crack riddle of important drug target 3
... Prostaglandin F2α isopropyl ester (15(R)-17-phenyl trinor ... isomer containing both a double bond ... hydroxyl group at C-15. Similar to ... is a potential impurity in most ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
... Mouse Anti Nop1p/Fibrillarin (monoclonal) ... nucleolar protein of bakers yeast, Saccharomyces ... is essential for yeast viability and ... human homologue of Nop1p is fibrillarin ...
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
Biology Products: